Abnormalities in the KRAS Gene and Treatment ... - PPM UMLub

The combined use of HDACi overcomes the resistance to MEK inhibitors caused by the downregulation of MAPK pathway negative regulators [261].







From target to KRAS broad range treatment - FLORE
Osimertinib, predicted by our computational platform during the course of this study, acts upstream of KRAS. G12C to inhibit EGFR, specifically ...
Targeting KRAS mutations in pancreatic cancer - Semantic Scholar
Our findings support TEAD inhibition as a therapeutic combination strategy to enhance the response rate and durability of direct KRAS inhibitor therapies.
Conquering oncogenic KRAS and its bypass mechanisms
One strategy to overcome resistance and to provide better disease control could be combination strategies to address the escape mechanisms in ...



Autres Cours:

A large scale proteome analysis of the gefitinib primary resistance ...